Citi analyst, Yigal Nochomovitz, reiterated his Buy rating on shares of ProQR Therapeutics N.V. (NASDAQ: PRQR) and announced a 90-day ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE